Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Shares Outstanding (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Shares Outstanding for 16 consecutive years, with $140.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 0.95% to $140.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $140.0 million, a 0.95% increase, with the full-year FY2024 number at $139.0 million, up 6.81% from a year prior.
  • Shares Outstanding was $140.0 million for Q3 2025 at Xtant Medical Holdings, roughly flat from $139.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $140.0 million in Q3 2025 to a low of $86.7 million in Q1 2021.
  • A 5-year average of $114.1 million and a median of $108.9 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: skyrocketed 555.7% in 2021, then increased 0.7% in 2022.
  • Xtant Medical Holdings' Shares Outstanding stood at $87.1 million in 2021, then increased by 25.04% to $108.9 million in 2022, then rose by 19.57% to $130.2 million in 2023, then grew by 6.81% to $139.0 million in 2024, then rose by 0.69% to $140.0 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Shares Outstanding are $140.0 million (Q3 2025), $139.3 million (Q2 2025), and $139.1 million (Q1 2025).